Drug Profile
JNJ 61803534
Alternative Names: JNJ61803534Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Unspecified in USA (PO, Tablet)
- 02 May 2017 Preclinical trials in Undefined indication in USA (PO) (NCT03139500)
- 02 May 2017 Janssen Research & Development plans a phase I trial in healthy volunteers in Belgium (NCT03139500)